Loading...
Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib
This phase 1 dose-escalation study determined the maximum tolerated dose (MTD) of oral pomalidomide (4 dose levels) administered on days 1 to 21 of each 28-day cycle in patients with relapsed and refractory multiple myeloma (RRMM). After four cycles, patients who progressed or had not achieved minim...
Na minha lista:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
American Society of Hematology
2013
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4123324/ https://ncbi.nlm.nih.gov/pubmed/23243282 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2012-08-450742 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|